Comparison of two ways (Intravenous and Nebulization) for giving a combination of two drugs (Dexmedetomidine and Ketamine) for passing tube (Endotracheal tube ) via nose with help of fiber scope in awake patients undergoing surgery

Comparison Between Intravenous Versus Nebulized Routes For Administering Dexmedetomidine And Ketamine Combination To Assist Awake Fiberoptic Intubation A Prospective Randomised Double Blind Study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/071493

Enrollment

Registered

2024-07-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H720- Central perforation of tympanic membrane Health Condition 2: M500- Cervical disc disorder with myelopathy Health Condition 3: H712- Cholesteatoma of mastoid Health Condition 4: H711- Cholesteatoma of tympanum Health Condition 5: H701- Chronic mastoiditis Health Condition 6: G892- Chronic pain, not elsewhere classified Health Condition 7: M265- Dentofacial functional abnormalities Health Condition 8: S320- Fracture of lumbar vertebra Health Condition 9: S024- Fracture of

Interventions

Intervention1: AWAKE FIBEROPTIC INTUBATION: Comparison Between IV Dexmedetomidine (1 microgram/kg) with Ketamine (0.5 milligram/kg) Vs Nebulized Dexmedetomidine (1 microgram/kg) with Ketamine (0.5 mil

Eligibility

Inclusion criteria

Inclusion criteria: Patients with ASA physical status Grade I and II Patients undergoing elective surgery under general endotracheal anesthesia Patients with Mallampati Class I and II

Exclusion criteria

Exclusion criteria: Patient refusal Psychiatric patients Emergency surgery Patients with severe bradycardia /heart block Pregnant and lactating mothers Patients having known allergy to any drugs used in the study Patients on long-term opioids or sedative medications Patients contraindicated to nasal intubation such as grossly distorted airway anatomy ,URTI and bleeding disorders

Design outcomes

Primary

Measure	Time frame
Cough score (severity of cough) during awake fiberoptic intubationTimepoint: Up to 2 Min after awake fiberoptic intubation	—

Secondary

Measure	Time frame
Intubating condition Vocal cord position Post intubation score Ramsay sedation score Hemodynamic parameters Side effects /Complication if any Timepoint: Up to 24- Hours postoperatively	—

Countries

India

Contacts

Public ContactDr Sakshi Agrawal

R.N.T Medical College

sharma0979@yahoo.co.in09214323557

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026